A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Definition, mechanism, and the clinical reality of pulmonary arterial hypertension at end of life. What the hospice team needs to understand on day one — right ventricular failure, IV prostacyclin, and the young women who carry this disease.
Pulmonary arterial hypertension is a rare, progressive disease of the small pulmonary arteries that kills through right ventricular failure. In PAH, the arterioles that carry blood from the right ventricle through the lungs undergo pathological remodeling — vasoconstriction, intimal fibrosis, medial hypertrophy, plexiform lesion formation, and thrombosis in situ — producing a relentless rise in pulmonary vascular resistance. The right ventricle, a thin-walled chamber evolved for low-pressure work, is forced to generate systemic-level pressures to drive blood through the pulmonary bed. It hypertrophies, dilates, and eventually fails. Right ventricular failure is the mechanism of death in virtually all PAH patients.[1][10]
PAH presents to hospice as WHO Functional Class III–IV disease: dyspnea at rest or with minimal exertion, syncope, peripheral edema, ascites, rising BNP, and a right ventricle operating at the limit of its compensatory capacity. The patient population is strikingly different from the elderly heart failure patients most hospice teams know — PAH disproportionately affects younger women, many in their 30s through 50s, with children at home and careers interrupted. The median age at diagnosis is approximately 50 years, though connective tissue disease-associated PAH skews older and idiopathic PAH can present in the third decade. The patient who arrives on hospice with PAH often carries a central venous catheter connected to a portable infusion pump delivering intravenous epoprostenol or treprostinil — the most powerful PAH therapy available, and the one whose interruption causes death within hours.[3][11][12]
What makes PAH unique in hospice is not the hemodynamics — it is the medication. No other hospice diagnosis routinely involves a continuously infusing vasoactive drug delivered through a permanent central line that cannot be stopped without causing rapid hemodynamic collapse. The hospice clinician who inherits an IV prostacyclin patient must understand the pump, the drug, the half-life, the backup protocol, and the consequences of interruption before the first visit ends. This is not optional knowledge — it is a patient safety obligation.[12][13]
Pulmonary arterial hypertension is a disease of the small pulmonary arteries — the vessels that carry deoxygenated blood from the right ventricle through the lungs to pick up oxygen. In PAH, these vessels narrow, stiffen, and obliterate through a process of vasoconstriction, endothelial dysfunction, smooth muscle hypertrophy, and thrombosis in situ. The result is a progressive rise in pulmonary vascular resistance (PVR) that forces the right ventricle — a thin-walled chamber designed for low-pressure work at ~25/10 mmHg — to pump against pressures it was never built to sustain. The mean pulmonary arterial pressure in severe PAH can exceed 50–60 mmHg, approaching systemic levels. The right ventricle hypertrophies, dilates, and eventually fails. The failing RV cannot fill the left ventricle adequately, producing low cardiac output, hypotension, syncope, and cardiogenic shock. Right heart failure is the cause of death in PAH.[10][14]
For the hospice clinician: every symptom in end-stage PAH traces back to the failing right ventricle. Dyspnea reflects inadequate pulmonary blood flow and hypoxemia. Edema and ascites reflect elevated right atrial pressure and venous congestion. Syncope reflects the RV's inability to maintain cardiac output during even mild vasodilation or exertion. Fatigue reflects chronically low cardiac index. Cachexia reflects the metabolic cost of a heart working at maximum capacity. Understanding RV failure as the unifying mechanism makes every clinical decision — diuresis, oxygen, medication adjustment, symptom management — coherent and logical.[14]
Right heart catheterization, echocardiography, 6-minute walk distance, and the diagnostic workup that distinguishes PAH from other causes of pulmonary hypertension. Most patients arrive with an established diagnosis — this section helps you read it.
Right heart catheterization (RHC) is the only definitive diagnostic test for PAH. No patient should receive PAH-specific therapy without a confirmatory RHC. The 2022 ESC/ERS guidelines define pulmonary hypertension and its hemodynamic subtypes as follows:[15][16]
Most PAH patients arrive at hospice with an established diagnosis. The hospice clinician's task is not to diagnose PAH but to read the existing workup and understand where the patient stands. Look for these elements in the chart:[15]
Your loved one's diagnosis of pulmonary arterial hypertension was made using specialized heart and lung testing — most importantly, a procedure called right heart catheterization, where a thin tube is threaded through a vein to directly measure the pressures inside the heart and lungs. This is the most accurate test for PAH, and it has already been done. At this point in the illness, the diagnostic workup is complete. The hospice team is not looking to do more testing — we are reading the results of the tests already done to understand exactly where your loved one's disease is and how we can best manage their comfort. If you see numbers like "mPAP," "PVR," or "cardiac index" in the medical notes, those are pressure and flow measurements from the heart catheterization that help us track how the heart is functioning.
El diagnóstico de hipertensión arterial pulmonar de su ser querido se realizó con pruebas especializadas del corazón y los pulmones. En este momento, las pruebas diagnósticas están completas. El equipo de hospicio no busca hacer más exámenes — estamos leyendo los resultados existentes para entender la enfermedad y manejar la comodidad de su ser querido.
WHO Group 1 PAH classification, BMPR2 genetics, connective tissue disease association, drug-induced PAH, and answering the question families always ask: "Why did this happen?"
PAH is specifically WHO Group 1 pulmonary hypertension — the disease category managed with PAH-targeted therapies. The Group 1 classification includes the following subtypes, each with distinct etiologies and prognostic implications:[15][21]
Families often ask why their loved one developed PAH. The honest answer is that in most cases, we do not fully know. Approximately 40% of PAH cases are "idiopathic" — meaning no identifiable trigger has been found. In some cases, PAH develops in the context of another condition like scleroderma or lupus, or it has a genetic component. But in no case did your loved one cause this disease through something they did or failed to do. PAH is not caused by smoking, diet, lack of exercise, or lifestyle choices. It is a disease of the blood vessels in the lungs — a biological process that was not preventable with the knowledge available. If your loved one's PAH is associated with a genetic mutation, that may have implications for other family members, and we can help arrange genetic counseling to address those questions. But please know: there is nothing anyone could have done differently to prevent this.
Even at hospice enrollment, genetic counseling referral is appropriate — and potentially life-saving for surviving family members. BMPR2 mutations are the most common genetic cause of PAH, present in ~75% of heritable cases and ~20–25% of apparently sporadic IPAH. Inheritance is autosomal dominant with ~20% penetrance, meaning first-degree relatives of a BMPR2 carrier have a 10% lifetime risk of developing clinical PAH.[22][23]
If the patient's PAH is idiopathic or familial and BMPR2 testing has not been performed, consider discussing it with the patient and family. For the hospice patient, the result does not change their care — but for their children and siblings, it can enable early screening, surveillance echocardiography, and potentially life-saving early intervention before symptoms develop. Children of a BMPR2 carrier should be offered testing, ideally through a genetics counselor experienced with PAH. This conversation is a legacy conversation — the patient can protect their family even at the end of their own life. Handle it with the weight it deserves.[22]
PAH-specific pharmacotherapy — the most complex medication regimen in all of hospice. IV prostacyclin, endothelin receptor antagonists, PDE5 inhibitors, and the combination therapy landscape.
PAH pharmacotherapy is the most complex medication regimen in all of hospice medicine. Three distinct molecular pathways drive pulmonary vascular disease — the prostacyclin pathway, the endothelin pathway, and the nitric oxide pathway — and modern treatment targets all three simultaneously using combination therapy. The landmark AMBITION trial demonstrated that upfront dual combination therapy (ambrisentan + tadalafil) reduced clinical failure by 50% compared to monotherapy. Subsequent observational data have shown that upfront triple combination therapy, including a parenteral prostacyclin, achieves 5-year survival of 91% in selected cohorts. Current ESC/ERS guidelines recommend risk-stratified combination therapy: dual oral therapy for low-to-intermediate risk patients, and triple therapy including parenteral prostacyclin for intermediate-high and high-risk patients.[8][9][15]
What this means for hospice is that the patient who enrolls with WHO Class III–IV PAH is typically on two to four PAH-specific medications targeting different pathways, often including intravenous prostacyclin. Each medication class has distinct side effect profiles, drug interactions, and consequences of discontinuation. The hospice clinician does not manage the PAH medication regimen independently — the PAH specialty center remains the prescribing authority for dose adjustments, particularly for parenteral prostacyclin. The hospice team's role is to understand what each medication does, recognize complications, ensure uninterrupted delivery, and coordinate with the PAH center. The sections below detail each pathway and the specific agents within it.[12][13]
Prostacyclin Pathway — The Most Potent PAH Therapy
The prostacyclin pathway produces the most powerful vasodilators available for PAH and is the only pathway with direct randomized-trial evidence of survival benefit. Prostacyclin (PGI₂) is an endogenous vasodilator and antiproliferative mediator that is deficient in PAH. Prostacyclin pathway agents include:[11][28]
Endothelin Receptor Antagonists (ERA) — Oral Pathway
Endothelin-1 (ET-1) is a potent vasoconstrictor and mitogen that is overexpressed in PAH. ERAs block ET-1 from binding its receptors (ETA and ETB) on pulmonary vascular smooth muscle cells, reducing vasoconstriction and vascular remodeling.[36]
PDE5 Inhibitors & sGC Stimulators — Nitric Oxide Pathway
Nitric oxide (NO) is an endogenous vasodilator that acts via the cGMP signaling pathway. PDE5 inhibitors prevent cGMP degradation; sGC stimulators enhance cGMP production independent of NO availability. Both result in pulmonary vasodilation and antiproliferative effects.[40]
IV epoprostenol has a half-life of 3–5 minutes. IV treprostinil has a half-life of ~4 hours. Abrupt discontinuation of either agent causes rebound pulmonary vasoconstriction, acute right ventricular failure, cardiovascular collapse, and death — within hours for epoprostenol and within hours to a day for treprostinil. This is not a gradual decline. It is a hemodynamic catastrophe that occurs faster than most rescue interventions can be mobilized in the home setting. Every hospice team managing a patient on IV prostacyclin must have a verified plan for: (1) uninterrupted drug delivery with backup cassettes and batteries at all times; (2) pump alarm recognition and response; (3) central line care and infection surveillance; and (4) a documented protocol for planned discontinuation if the patient chooses to stop — which requires pre-arranged palliative sedation before the infusion rate is changed. The PAH center must be involved in every decision regarding IV prostacyclin dose or status.[29][30][11]
Evidence-based criteria for continuing PAH-directed therapy including IV prostacyclin continuation in hospice. This is not about giving up or holding on — it is about reading the data correctly.
PAH is the rare disease in hospice where disease-directed therapy and comfort care are not opposing goals — they are the same goal. IV prostacyclin reduces dyspnea, prevents acute hemodynamic collapse, and maintains functional status. Oral PAH-specific therapies lower pulmonary vascular resistance and delay right ventricular failure. Aggressive diuresis relieves the fluid overload that drives end-stage symptoms. Unlike most oncologic or cardiac diagnoses where treatment continuation on hospice is an exception requiring justification, in PAH, continuation of the medication regimen is the comfort plan. The critical question at hospice enrollment is not whether to continue therapy — it is whether the hospice provider has the infrastructure and expertise to support it.[1][6]
Before accepting a PAH patient on IV prostacyclin, the hospice agency must honestly answer: Can we support continuous IV infusion via central venous catheter? Do we have nurses trained in prostacyclin pump management? Can we ensure 24/7 access to pump troubleshooting and central line care? Do we have a direct communication pathway with the PAH center? If the answer to any of these is no, the patient needs a different provider — and helping them find one is the right clinical decision. A hospice team that accepts an IV prostacyclin patient without the infrastructure to support the medication is creating a safety hazard, not providing comfort care.
Knowing when PAH treatment stops helping is not clinical failure. Refractory RV failure, REVEAL high-risk scores, and the prostacyclin discontinuation decision — the most ethically complex medication decision in all of hospice.
Knowing when PAH therapy has reached its ceiling is not clinical failure — it is the most important clinical recognition in this disease. PAH is unique among hospice diagnoses because the primary life-sustaining therapy (IV prostacyclin) is also the primary comfort therapy. The decision to shift from escalation to maintenance, or from maintenance to planned discontinuation, requires a level of clinical nuance that exceeds most other end-of-life medication decisions. The thresholds below are not arbitrary — they reflect hemodynamic, functional, and prognostic markers validated in the REVEAL registry and international PAH guidelines that indicate the point at which further escalation will not reverse the trajectory.[2][5]
Discontinuation of IV prostacyclin is not like stopping a medication — it is actively ending the pharmacological support keeping the heart functioning. Death occurs within hours. This conversation must be approached with the same gravity, documentation, and preparation as withdrawal of mechanical ventilation. It is the most ethically complex medication decision in all of hospice care.
The prostacyclin discontinuation discussion should begin as a planning conversation early in the hospice enrollment, not as an emergency decision when the patient is actively dying. Raising it early allows the patient time to reflect, ask questions, involve family, consult spiritual advisors, and make a fully autonomous decision without the pressure of clinical deterioration. Frame it as: "At some point, some patients with your condition decide they are ready to stop the IV medication. If that day comes for you, we want to be prepared so that we can make sure you are completely comfortable. This is not a decision you need to make now — but I want you to know it is your right, and we will support whatever you choose."
Evidence-graded integrative, interventional, and complementary approaches for PAH. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
PAH hospice care requires approaches that cross the traditional boundary between disease-directed and comfort-directed therapy. Several interventions below would be considered "disease-directed" in other contexts but serve primarily as comfort measures in end-stage PAH — because in this disease, maintaining hemodynamic stability is comfort care. Evidence grading: Grade A = randomized controlled trial or strong guideline support; Grade B = multi-observational, meta-analysis, or strong case series; Grade C = limited clinical evidence with preclinical rationale; Grade D = expert opinion or case report level.[1]
This is the most important intervention in PAH hospice and it may appear counterintuitive to clinicians unfamiliar with the disease. Hospice clinicians who are accustomed to medication simplification may reflexively consider stopping IV prostacyclin as a comfort measure — this must never happen without explicit patient request and full informed consent about the consequence (death within hours). IV epoprostenol demonstrated a 66% reduction in mortality in Barst et al.'s landmark 1996 NEJM trial — the only PAH therapy to show survival benefit in an RCT. Beyond survival, prostacyclin reduces dyspnea, improves cardiac output, and prevents the acute rebound pulmonary vasoconstriction that makes discontinuation lethal. In the hospice context, IV prostacyclin is simultaneously life-sustaining therapy and the most effective comfort medication in the PAH pharmacopeia. Maintain it. Coordinate with the PAH center. Ensure the hospice provider has the infrastructure to support it safely.[7][8]
Parenteral and oral morphine for dyspnea is evidence-based across all cardiopulmonary diagnoses and is specifically supported in PAH. The BOHICA registry and multiple case series document opioid use in PAH patients with WHO Class III–IV dyspnea. Morphine reduces the central perception of breathlessness, decreases respiratory drive–related air hunger, and produces mild anxiolysis — all directly targeting the cardinal symptom of end-stage PAH. Start low and titrate in the PAH population because right-heart-failure patients may have hepatic congestion affecting drug metabolism. Hydromorphone 0.5–1 mg PO q4h is an alternative in morphine-intolerant patients. Opioids do not replace prostacyclin — they complement it. The patient on IV prostacyclin with breakthrough dyspnea should receive opioids without hesitation.[32][33]
Multiple RCTs demonstrate that cool air directed across the face via a handheld fan reduces the subjective perception of dyspnea by stimulating the trigeminal nerve (V2 branch) and modulating the central processing of breathlessness. The Cochrane review of fan therapy for breathlessness supports its use in chronic cardiopulmonary disease. In PAH, where dyspnea is driven by low cardiac output and ventilation-perfusion mismatch rather than airway obstruction, fan therapy provides a non-pharmacologic comfort layer that is simple, free, available 24/7, and entirely without side effects. Teach every PAH hospice patient and every caregiver to use a fan. It does not replace oxygen or opioids — it supplements them. Patients report significant subjective improvement even when objective parameters (SpO₂, respiratory rate) do not change.[34]
When a patient with full decisional capacity requests discontinuation of IV prostacyclin, palliative sedation is not optional — it is an ethical requirement. The National Hospice and Palliative Medicine Organization (NHPMO), the American Academy of Hospice and Palliative Medicine (AAHPM), and international palliative care guidelines support palliative sedation for refractory symptoms at end of life, including the anticipated refractory dyspnea that follows prostacyclin withdrawal. The protocol mirrors ventilator withdrawal sedation: achieve deep sedation first, then discontinue the life-sustaining therapy. Midazolam provides rapid-onset anxiolysis and sedation; morphine addresses anticipated dyspnea and pain from acute RV failure. Additional agents (lorazepam, phenobarbital) may be needed if initial dosing is inadequate. The patient must be comfortable before the infusion is stopped. This is not euthanasia — it is standard palliative sedation for withdrawal of life-sustaining treatment.[30][31]
Creation of a right-to-left interatrial shunt via blade or graded balloon atrial septostomy decompresses the failing right ventricle by allowing blood to bypass the high-resistance pulmonary vasculature. This improves systemic cardiac output and reduces RV wall stress at the cost of reduced systemic oxygen saturation (patients become cyanotic but feel better because cardiac output improves). Multiple case series (Sandoval et al., Kurzyna et al.) demonstrate hemodynamic improvement and symptomatic relief in WHO Class IV patients refractory to medical therapy. Procedural mortality ranges from 5–15% depending on patient selection and center experience. Atrial septostomy is used as a bridge to lung transplant or, in patients not transplant-eligible, as a palliative intervention to improve functional status and quality of life. It is not appropriate in the actively dying patient, but in selected WHO Class IV patients earlier in the trajectory who are deteriorating despite maximal medical therapy, referral to a center experienced in the procedure is a meaningful palliative option.[28]
Spironolactone specifically targets the aldosterone-driven fluid retention and myocardial fibrosis that characterize RV failure in PAH. The RALES trial demonstrated mortality reduction with spironolactone in left heart failure (NYHA III–IV), and the mechanism — aldosterone blockade reducing myocardial fibrosis, sodium retention, and potassium wasting — applies directly to the failing right ventricle. Observational data in PAH populations (Maron et al.) suggest improved fluid balance and reduced hospitalization with aldosterone antagonism. In practice, spironolactone at 25–100 mg daily added to loop diuretic therapy reduces ascites, peripheral edema, and dyspnea from volume overload without the aggressive preload reduction that high-dose furosemide alone can produce — a critical distinction in the preload-dependent failing RV. Spironolactone is an underused comfort drug in PAH hospice. Monitor serum potassium, particularly when renal function declines.[23][24]
For selected patients on IV prostacyclin who find the central line, pump, and continuous infusion burdensome — and who express a desire for reduced medical equipment tethering — transition from IV to inhaled prostacyclin may be considered as a quality-of-life decision. Inhaled treprostinil (Tyvaso) delivers prostacyclin directly to the pulmonary vasculature via nebulization 4–6 times daily. The TRIUMPH trial demonstrated improvement in 6-minute walk distance when inhaled treprostinil was added to oral therapy. Transition from IV to inhaled is a step-down in potency and carries hemodynamic risk — it must be managed by the PAH center, not the hospice team independently. This is appropriate only when the patient explicitly prioritizes freedom from the pump over maximal hemodynamic support, and when the PAH center agrees the patient's hemodynamic profile can tolerate the transition. It is a comfort-prioritizing decision, not a disease-escalation one.[9][10]
Digoxin has a long history in right heart failure management predating modern PAH therapy. A small acute hemodynamic study (Rich et al.) demonstrated improved cardiac output with IV digoxin in PAH patients. The ESC/ERS guidelines include digoxin as a "may be considered" supportive therapy in PAH with RV failure, particularly in patients with atrial tachyarrhythmias (atrial flutter, atrial fibrillation) where rate control is needed. In the hospice context, digoxin at low doses (0.125 mg daily, targeting serum levels 0.5–0.9 ng/mL to minimize toxicity) may provide modest inotropic support and rate control. Monitor for digoxin toxicity — nausea, visual disturbance, bradycardia — particularly in the setting of declining renal function and diuretic-induced electrolyte shifts common in end-stage PAH. Digoxin is not a first-line comfort intervention, but it has a role in selected patients with concurrent atrial arrhythmia and RV failure.[23][35]
In most diagnoses, hospice enrollment signals a simplification of the medication regimen. In PAH, the opposite is true. The PAH medication regimen is the comfort plan. IV prostacyclin is the comfort drug. Triple oral therapy is the comfort regimen. Diuresis is the comfort intervention. The hospice clinician who approaches a PAH patient with the reflexive instinct to "simplify medications" risks destabilizing the patient and precipitating the crisis they were trying to prevent. Learn the medications, learn the pump, learn the alarm protocol — and maintain the regimen that the PAH center has spent months or years optimizing.
PAH pharmacotherapy is among the most interaction-prone medication regimen in hospice. Evidence grading, dosing, drug interaction flags, and explicit contraindications — two rules: does it interact with PAH medications, and does it cause pulmonary vasoconstriction?
PAH pharmacotherapy is among the most complex and most interaction-prone medication regimen in all of hospice. Endothelin receptor antagonists (ambrisentan, macitentan, bosentan) are CYP3A4 substrates and inducers — any supplement that alters CYP3A4 activity can raise or lower ERA plasma levels with potentially dangerous hemodynamic consequences. PDE5 inhibitors (sildenafil, tadalafil) interact with any vasodilatory herb or supplement with potentially severe hypotension. Riociguat is absolutely contraindicated with PDE5 inhibitors and with nitric oxide donors including nitrate-containing supplements — the combination can cause fatal hypotension. IV prostacyclin requires intact central venous access that could be endangered by any supplement affecting coagulation — a central line infection or catheter-related thrombosis from a supplement-induced coagulopathy can be lethal. And above all — any supplement with vasoconstrictive properties could worsen pulmonary vasoconstriction and precipitate hemodynamic collapse in a patient whose pulmonary vasculature is maximally sensitive to vasomotor tone changes.
Two rules apply to every supplement recommendation in PAH: (1) Does it interact with the PAH medication regimen? (2) Does it cause pulmonary vasoconstriction? If yes to either, do not recommend it.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Magnesium Glycinate | Grade C | 200–400 mg PO daily | Diuretic-induced magnesium depletion is common in PAH patients on furosemide and spironolactone. Hypomagnesemia increases arrhythmia risk (atrial and ventricular) in the already-vulnerable failing RV and worsens muscle cramps that impair sleep and quality of life. Magnesium repletion may reduce arrhythmia burden and relieve cramps.[36] | No significant vasodilatory or vasoconstrictive effect at recommended doses. No CYP interactions with ERAs, PDE5 inhibitors, or prostacyclin. One of the safest supplements in PAH. Check serum magnesium before supplementing — some patients are already receiving IV magnesium from the PAH center. Reduce dose if GFR <30 mL/min due to impaired renal magnesium excretion. Avoid magnesium oxide (poor bioavailability, causes diarrhea — counterproductive in patients already experiencing prostacyclin-related diarrhea). |
| Melatonin | Grade C | 1–3 mg PO at bedtime | Sleep disruption is pervasive in end-stage PAH — driven by dyspnea, nocturnal hypoxemia, anxiety, pump alarms, and the psychological burden of the disease. Melatonin supports circadian rhythm entrainment and may improve sleep quality without respiratory depression.[37] | No vasodilatory effect at physiologic doses. Minimal drug interactions with PAH regimen — does not affect CYP3A4, does not interact with PDE5 inhibitors or ERAs. Does not affect coagulation or central line integrity. One of the safest supplements in this population. Avoid doses >5 mg — higher doses may cause morning drowsiness that compounds the fatigue of RV failure. Do not combine with benzodiazepines without clinician guidance as both are CNS depressants. |
| CoQ10 / Ubiquinol | Grade C | 100 mg PO daily (maximum) | Theoretical RV mitochondrial support rationale: the failing right ventricle is an energy-depleted myocardium with impaired oxidative phosphorylation. CoQ10 is an electron carrier in the mitochondrial respiratory chain. Small studies in left heart failure suggest modest benefit in functional capacity and quality of life.[38] | No CYP interactions at 100 mg daily. Minimal hemodynamic effect — does not cause significant vasodilation or vasoconstriction. Important: CoQ10 has mild vitamin K-like activity and may reduce the INR in patients anticoagulated with warfarin — a significant concern in PAH patients who are frequently on warfarin for in situ pulmonary thrombosis. Monitor INR if CoQ10 is started in a warfarin-treated patient. Consider avoiding in patients on warfarin or switching to a direct oral anticoagulant (DOAC) if CoQ10 is desired. |
| Ginger (low-dose) | Grade C | 250–500 mg PO daily or ginger tea 1–2 cups daily | Nausea from prostacyclin therapy (jaw pain, GI side effects are dose-limiting) and from hepatic congestion secondary to RV failure. Ginger has demonstrated antiemetic properties in RCTs for chemotherapy-induced and pregnancy-related nausea via 5-HT3 receptor antagonism.[39] | At low doses (≤500 mg daily), ginger has minimal CYP interaction and no significant vasomotor effects. At high doses (>2 g daily), ginger may have mild antiplatelet activity — relevant in patients with central venous catheters where catheter-related thrombosis risk must be balanced against bleeding risk. Keep doses low. Avoid concentrated ginger extracts in patients on warfarin. Ginger tea at standard preparation is generally safe. |
| L-Arginine | Grade D | NOT RECOMMENDED — see cautions | L-arginine is the substrate for endogenous nitric oxide (NO) synthesis via nitric oxide synthase. Theoretical rationale: increased NO availability → pulmonary vasodilation → reduced PVR. A small study (Nagaya et al.) showed modest improvement in hemodynamics with oral L-arginine in PAH.[40] | ⚠ MAJOR CAUTION: L-arginine increases nitric oxide production. Riociguat is absolutely contraindicated with NO donors — the combination causes fatal hypotension. PDE5 inhibitors (sildenafil, tadalafil) potentiate the NO-cGMP pathway — concurrent L-arginine supplementation can produce severe systemic hypotension. Even in patients not on riociguat or PDE5 inhibitors, uncontrolled NO-mediated vasodilation in a patient whose cardiac output depends on a narrow hemodynamic window is dangerous. The risk-benefit ratio is unacceptable in end-stage PAH on modern therapy. Do not recommend. |
| Omega-3 Fatty Acids (EPA/DHA) | Grade C | 1–2 g EPA+DHA daily | Anti-inflammatory effect may modulate the inflammatory component of pulmonary vascular remodeling. Potential reduction in triglycerides. Modest evidence for benefit in left heart failure (GISSI-HF trial showed small mortality reduction). May support endothelial function.[41] | At standard doses (1–2 g daily), omega-3s have minimal CYP interaction and no vasoconstrictive effect. Mild antiplatelet effect at high doses (>3 g daily) — relevant for patients with central venous catheters. Keep doses at ≤2 g daily. No significant interaction with ERAs, PDE5 inhibitors, or prostacyclin. Fish oil burps and GI upset may compound prostacyclin-related nausea and diarrhea in sensitive patients — enteric-coated formulations may reduce this. Overall, one of the safer supplements in this population at moderate doses. |
PAH patients are often younger, health-literate, and proactive. They may be taking supplements before hospice enrollment and may not volunteer this information unless asked directly. At every medication reconciliation, ask specifically about supplements, herbal products, protein powders, and any product purchased from a health food store or online. Frame it as safety, not judgment: "Your PAH medications are highly specialized and have very specific interactions. I need to know everything you're taking — including supplements — so I can make sure nothing interferes with the medications keeping your heart stable." Most patients, once they understand the rationale, will disclose willingly and appreciate the clinical specificity.
A guide, not a prediction. PAH-specific milestones built around the RV failure trajectory, prostacyclin treatment escalation, and the lung transplant timeline.
PAH trajectory is defined by right ventricular adaptation and failure, not by tumor staging or organ metastasis. The timeline below tracks the progression from compensated WHO Class II–III disease through decompensated RV failure and death. Several factors dramatically alter this trajectory: connective tissue disease–associated PAH (SSc-PAH) carries the worst prognosis of all subtypes with median survival 1–3 years from diagnosis.[4] Idiopathic PAH on modern triple combination therapy may sustain WHO Class II–III for years.[12] REVEAL high-risk score (>7) at any point predicts 1-year mortality exceeding 20%.[5] Portopulmonary hypertension and HIV-PAH carry additional comorbidity burdens that compress the timeline independently. Use this guide at the bedside to orient families and clinicians to the current phase — and to plan ahead for the next one before it arrives.
If at any point in the DAYS-WKS or HRS-DAYS phase the patient or surrogate makes a fully informed, autonomous decision to discontinue IV prostacyclin, the timeline compresses to hours. Rebound pulmonary vasoconstriction from prostacyclin withdrawal causes acute hemodynamic collapse. Palliative sedation with midazolam must be initiated before the infusion rate is reduced. This is a planned death — it requires preparation, documentation, and the PAH center's involvement. It is ethically equivalent to withdrawal of ventilator support, and it requires the same level of clinical planning and family preparation.[34]
Symptom-targeted pharmacology for PAH. IV prostacyclin management, RV failure diuresis, PAH-specific medication interactions, and the comfort kit essentials for a disease where the most important medication must never be stopped.
This is the most important pharmacological safety statement in PAH hospice. IV prostacyclin (epoprostenol or treprostinil) delivered via continuous central venous infusion is a life-sustaining medication. Interruption of IV prostacyclin causes rebound pulmonary vasoconstriction, acute right ventricular failure, and death within hours in most patients. Epoprostenol has a half-life of 3–5 minutes — even brief interruptions are dangerous.[6]
The clinical team must have a verified plan for: (1) maintaining uninterrupted IV prostacyclin delivery with backup medication cassettes and backup batteries at all times, (2) central venous line care and infection monitoring, (3) pump alarm response — every family member who may be home must know the alarm protocol, and (4) a planned discontinuation protocol if the patient chooses to stop — which requires palliative sedation preparation before the infusion rate is changed.[34]
Additionally: PAH medications have multiple serious drug interactions. Endothelin receptor antagonists are CYP3A4 substrates. PDE5 inhibitors are potent vasodilators that interact with nitrates and other vasodilatory agents. Riociguat is absolutely contraindicated with PDE5 inhibitors. Review the complete medication list against the PAH regimen at every visit. Never add a new medication without verifying interactions with the PAH center.[8]
The dominant pharmacological reality in PAH hospice is the IV prostacyclin infusion. Every other medication decision is secondary to maintaining the prostacyclin. Beyond the prostacyclin, PAH patients typically arrive on multiple oral PAH-specific agents (ERA, PDE5 inhibitor, and possibly selexipag), diuretics for RV failure volume management, and anticoagulation. The comfort medication layer — opioids for dyspnea, benzodiazepines for anxiety and terminal agitation, and anticholinergics for secretions — is added on top of this complex baseline. Coordinate all PAH-specific medication changes with the PAH center. The hospice clinician manages comfort; the PAH specialist manages the disease-directed regimen. Both roles are essential.[6]
| Drug | Class / Target | Starting Dose | Notes / Cautions |
|---|---|---|---|
| IV Epoprostenol (Flolan, Veletri) or IV Treprostinil (Remodulin) | Prostacyclin / Life-sustaining PAH therapy | Maintain current dose — typically 20–40 ng/kg/min for epoprostenol; variable for treprostinil | THE most important medication in PAH hospice. Continue — never stop abruptly. Ensure backup cassettes are present (refrigerated for Flolan; room temperature for Veletri and Remodulin). Ensure backup batteries are charged. Ensure the pump alarm protocol is posted and understood by every family member who might be home. Coordinate all dose changes with the PAH center. In comfort-focused care, the goal is maintaining the current dose or the dose providing optimal symptom relief without intolerable side effects — jaw pain, diarrhea, flushing, headache are common dose-limiting prostacyclin effects. Dose escalation may be appropriate in a deteriorating hospice patient if consistent with patient goals and PAH center recommendation. ⚠ Abrupt discontinuation → hemodynamic collapse → death within hours.[6] Flolan requires ice packs or cold pouch; Veletri is thermostable at room temperature for up to 72 hours. Know which formulation the patient uses — storage requirements differ and confusion between them is a safety hazard. |
| Ambrisentan (Letairis) | ERA / PAH-specific oral therapy | 5–10 mg PO daily | Continue if patient can swallow and is tolerating. Selective ETA receptor antagonist. Fewer CYP interactions than bosentan. Do not stop without PAH center guidance — abrupt ERA withdrawal may worsen pulmonary hemodynamics. Peripheral edema is a common side effect that overlaps with RV failure edema — distinguish drug effect from disease progression.[9] |
| Macitentan (Opsumit) | ERA / PAH-specific oral therapy | 10 mg PO daily | Continue if patient can swallow. Dual ETA/ETB receptor antagonist. SERAPHIN trial demonstrated morbidity/mortality benefit in combination therapy. CYP3A4 substrate — avoid strong CYP3A4 inhibitors (azole antifungals, some macrolide antibiotics). Monitor hemoglobin — ERA class effect causes anemia. Do not discontinue without PAH center guidance.[10] |
| Bosentan (Tracleer) | ERA / PAH-specific oral therapy | 125 mg PO BID | Continue if tolerating. Dual ETA/ETB antagonist. Requires monthly LFT monitoring — hepatotoxicity is a class-specific risk (elevated transaminases in ~10% of patients). ⚠ In comfort-focused care, discuss with patient and PAH center whether continued monthly LFT monitoring is consistent with goals. Strong CYP3A4 and CYP2C9 inducer — interacts with warfarin, sildenafil, hormonal contraceptives, and many other medications. Do not stop without PAH center guidance.[8] |
| Sildenafil (Revatio) | PDE5 inhibitor / PAH-specific oral therapy | 20 mg PO TID | Continue if patient can swallow. Vasodilator — reduces pulmonary vascular resistance. Three-times-daily dosing can be burdensome. ⚠ Absolutely contraindicated with riociguat — fatal hypotension. Do not use with nitrates or nitric oxide donors. Hypotension risk increases with concurrent prostacyclin. Common side effects: headache, flushing, visual disturbance. In comfort setting, continue for dyspnea relief and hemodynamic support.[11] |
| Tadalafil (Adcirca) | PDE5 inhibitor / PAH-specific oral therapy | 40 mg PO daily | Continue if patient can swallow. Once-daily dosing is less burdensome than sildenafil TID. Same contraindication with riociguat and nitrates. PHIRST trial demonstrated improvement in 6MWD and hemodynamics. In comfort-focused care, preferred over sildenafil for simplicity if switching is appropriate. Coordinate any switch with the PAH center.[11] |
| Riociguat (Adempas) | sGC stimulator / PAH-specific oral therapy | 0.5–2.5 mg PO TID | Continue if patient is on it and tolerating. Soluble guanylate cyclase stimulator — different mechanism from PDE5 inhibitors. ⚠ Absolutely contraindicated with PDE5 inhibitors (sildenafil, tadalafil) — never use concomitantly. Contraindicated with nitrates and nitric oxide donors. Teratogenic — pregnancy must be excluded. In comfort-focused care, continue for hemodynamic support if patient can swallow. PATENT trial evidence supports efficacy.[13] |
| Selexipag (Uptravi) | IP receptor agonist / Oral prostacyclin pathway | 200–1,600 mcg PO BID (individualized) | Continue if tolerating. Oral selective IP prostacyclin receptor agonist — GRIPHON trial demonstrated morbidity benefit. Side effects mirror prostacyclin class: headache, jaw pain, diarrhea, nausea, myalgia. Dose is individually titrated — do not adjust without PAH center guidance. If patient cannot swallow, selexipag cannot be crushed — discuss transition plan with PAH center.[14] |
| Furosemide (Lasix) | Loop diuretic / RV failure volume management | 40–160 mg PO/IV daily; titrate to euvolemia | Essential for managing RV failure volume overload — peripheral edema, ascites, pulmonary congestion, and dyspnea. Titrate aggressively to relieve symptoms. Monitor potassium — hypokalemia risk, especially with concurrent digoxin. In terminal phase, diuretic resistance is common as cardiac output falls; if oral absorption fails, switch to SQ or IV furosemide. Monitor renal function — rising creatinine may indicate cardiorenal syndrome rather than diuretic excess.[28] |
| Spironolactone (Aldactone) | Aldosterone antagonist / RV failure adjunctive diuresis | 25–100 mg PO daily | The unsung hero of RV failure management in PAH. Targets the aldosterone-driven fluid retention that characterizes RV failure. Potassium-sparing — helps offset furosemide-induced hypokalemia. Reduces ascites and peripheral edema without the preload reduction risk of aggressive loop diuresis alone. Monitor potassium, especially in renal impairment. In comfort-focused care, continue as long as patient can swallow — one of the most effective comfort medications in PAH.[28] |
| Morphine | Opioid / Dyspnea + Pain | 2.5–5 mg PO/SQ q4h; titrate to dyspnea relief | First-line for PAH dyspnea in comfort-focused care. Evidence supports opioid use for refractory dyspnea across all cardiopulmonary diagnoses. Start low, titrate to effect. In opioid-naive PAH patients, 2.5 mg SQ is an appropriate starting dose. Respiratory depression at appropriate doses is not a clinically significant risk in dyspneic patients — the dyspnea itself is the indication, not pain alone. Transition to continuous SQ infusion if breakthrough dyspnea is frequent. Morphine also reduces preload, which may provide modest hemodynamic benefit in RV failure.[30] |
| Lorazepam (Ativan) | Benzodiazepine / Anxiety | 0.5–1 mg PO/SL/SQ q4–6h PRN | Adjunctive for anxiety that accompanies dyspnea — the sensation of suffocation drives profound anxiety in PAH patients, and the anxiety worsens the dyspnea in a self-amplifying cycle. Use PRN for acute anxiety episodes. Limited evidence for dyspnea alone — pair with morphine for combined dyspnea-anxiety management. Sublingual route available when swallowing fails. Avoid scheduled high-dose use unless anxiety is refractory.[30] |
| Midazolam (Versed) | Benzodiazepine / Terminal agitation + Palliative sedation | 2.5–5 mg SQ/IV PRN; 1–5 mg/hr continuous SQ/IV for palliative sedation | For terminal agitation, refractory dyspnea crisis, and palliative sedation. Critical role in prostacyclin discontinuation: if the patient has made an informed decision to discontinue IV prostacyclin, midazolam-based palliative sedation must be initiated and patient must be comfortable before the prostacyclin infusion rate is reduced. Have midazolam drawn, labeled, and at the bedside in every PAH comfort kit. Onset 3–5 minutes SQ; rapid titration possible. Short half-life allows dose adjustment.[34] |
| Glycopyrrolate (Robinul) | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Reduces terminal airway secretions (death rattle) without crossing the blood-brain barrier — preferred over hyoscine (scopolamine) in conscious or semi-conscious patients because it does not cause CNS sedation, agitation, or delirium. Begin at first sign of audible secretions — works best preventively. Explain to families that secretions are not causing the patient to drown or choke.[30] |
| Digoxin | Cardiac glycoside / RV contractility support | 0.125–0.25 mg PO daily | Some PAH patients arrive on digoxin for RV contractility support or rate control of atrial flutter/fibrillation (common in RV failure). Evidence for digoxin benefit in PAH-specific RV failure is limited. In comfort-focused care, continue if patient is tolerating and it is part of the PAH center's regimen. Narrow therapeutic window — toxicity risk increases with renal impairment and hypokalemia from diuretics. ⚠ Monitor digoxin level if continuing; discontinue if toxicity signs appear (nausea, visual changes, bradycardia).[28] |
| Warfarin or Anticoagulation | Anticoagulant / Thrombosis prophylaxis | Warfarin dose per INR target (typically 1.5–2.5 in PAH) | Many PAH patients are anticoagulated based on historical practice and some evidence of in-situ pulmonary thrombosis in PAH. IPAH patients more commonly anticoagulated than CTD-PAH. In comfort-focused care, the decision to continue anticoagulation is individualized — INR monitoring may become burdensome; bleeding risk increases with hepatic congestion and thrombocytopenia; discuss with PAH center and patient whether continued anticoagulation is consistent with goals. If discontinuing, wean rather than stopping abruptly to reduce rebound thrombosis risk. ⚠ Bosentan reduces warfarin levels via CYP induction — requires INR monitoring if both are continued.[28] |
| Supplemental Oxygen | Supportive / Hypoxemia | Titrate to SpO₂ ≥ 90% at rest; 2–6 L/min via nasal cannula | Hypoxia causes pulmonary vasoconstriction — supplemental oxygen reduces hypoxic vasoconstriction and indirectly decreases RV afterload. Continue in all hypoxemic PAH patients (SpO₂ <90% at rest or with exertion). In the terminal phase, oxygen may provide comfort even if SpO₂ target is not achievable — dyspnea perception and air hunger are what we are treating, not the number. A fan directed at the face may be equally effective for air hunger sensation.[30] |
High-yield clinical pearls for the PAH hospice team. IV prostacyclin safety assessment, PAH center coordination, the discontinuation conversation, syncope management, and racial disparities in PAH care.
Young women and the loss of future, the tethered life on IV prostacyclin, transplant hope and its loss, the discontinuation ambivalence, and the existential weight of a disease that disproportionately affects people in the middle of building their lives.
Pulmonary arterial hypertension attacks identity before it takes life. PAH disproportionately affects younger women — the female-to-male ratio is 2.3–3.5:1, and mean age at diagnosis is approximately 50 years, with many patients diagnosed in their 30s and 40s.[1] These are patients who expected decades more of parenthood, partnership, career, and future. The psychosocial burden of PAH is compounded by the physical tethering of IV prostacyclin therapy, the loss of lung transplant candidacy, the contraindication of pregnancy, and the knowledge that the medication keeping you alive is also the thing that defines every moment of your day. Depression, anxiety, and existential distress in PAH are not complications — they are integral features of the disease experience, and they require the same systematic clinical attention as right ventricular failure.[43]
Your job is not to fix this grief. Your job is to name it, to make space for it, to ensure it does not go unwitnessed, and to connect the patient with chaplaincy, social work, psychology, and legacy planning resources from enrollment — not at crisis.
PAH-specific risk factors for depression: Depression prevalence in PAH ranges from 25–55% depending on screening instrument and disease severity — substantially higher than general hospice populations.[43]
PAH generates anxiety through mechanisms unique in hospice:
PAH disproportionately affects women of reproductive age. A diagnosis at 35 or 40 with a median survival of 4–7 years on modern therapy affects women who have not yet finished the life they planned — children who need a mother, careers interrupted, pregnancies now contraindicated. Pregnancy in PAH carries 30–50% maternal mortality in WHO Class III–IV disease; it is absolutely contraindicated, and the conversation about this loss must be had explicitly.[44] The grief in the room of a young PAH patient is categorically different from the grief of an elderly patient with a different cardiac diagnosis. Legacy work, life completion, children's needs, and relationship planning must begin at enrollment — not in the final days. Ask directly: "What do your children know about your illness? What do you want them to know? What do you want them to have from you?"
The patient on IV prostacyclin lives tethered to a machine. They carry a backpack containing the pump and medication cassette everywhere — to dinner, to their child's school event, to bed. They sleep next to a charging station. They cannot travel more than a few hours from their backup supply. Every social activity, every moment of spontaneity, every intimate encounter is planned around the medication. The pump beeps. The tubing gets caught. The dressing must be changed. The cassette must be swapped. The backup battery must be charged. The ice pack must be refreshed. This is not a medication — it is a way of life, and its psychosocial toll is enormous and systematically under-addressed.[45]
Ask directly: "How has having the pump changed your daily life? Is there something you cannot do that you wish you could? How has it affected your relationship with your partner? How has it affected how you see yourself?" Many patients have never been asked these questions. The pump is so medically normalized by PAH centers that its identity-altering effects are invisible to clinicians who do not ask. Intimacy, self-image, spontaneity, and social participation are all affected — and all deserve clinical attention.[45]
Spirituality is not the same as religion. Patients with no religious affiliation still carry spiritual needs — meaning, legacy, connection, peace, and the question of what their life meant. Use the FICA framework: Faith/beliefs, Importance, Community, Address. In PAH, the spiritual assessment must address the specific existential challenges of this disease:[43]
PAH transforms relationships in ways that no other cardiac diagnosis does at this age. These are often young couples — in their 30s, 40s, 50s — who expected decades together. The partner of a PAH patient on IV prostacyclin is not just a spouse — they are a pump manager, a medication scheduler, a central line caretaker, and a 24-hour clinical monitor. They check alarms at 3 AM. They change dressings. They call the PAH center. They track cassette expiration dates. They are exhausted, terrified, and often unable to acknowledge their own needs because the patient's needs are so overwhelming.[47]
Parenthood is often impossible. Pregnancy in PAH carries 30–50% maternal mortality — it is not a risk; it is a near-prohibition.[44] For young couples who hoped for children, this loss is devastating. For couples who already have children, the fear of leaving those children motherless — combined with the daily reality of IV therapy management — creates a relational burden that must be addressed directly. Ask the partner separately: "How are you doing — not as a caregiver, but as a person? What have you had to give up?"
Children know more than adults think they know. They hear the pump alarms. They see the backpack. They notice their mother's breathlessness on the stairs. They feel the anxiety in the house. Silence does not protect children — it isolates them. Age-appropriate honesty is essential:
Passive wish for death — "I'm ready to go," "I'm tired of fighting" — is common in PAH and often existentially appropriate, particularly in patients exhausted by the demands of IV prostacyclin management. It is not the same as active suicidal ideation. Assessment requires careful distinction:[43]
Do not conflate these categories. Do not avoid the question. Do not assume the patient who asks about stopping the pump is suicidal. They may be exercising the most important autonomous decision of their life.
In heritable PAH (BMPR2 mutations), the patient may carry guilt about potentially transmitting the disease to their children — and the children may carry fear of developing it themselves. BMPR2 testing and genetic counseling should be offered to first-degree relatives. The psychosocial burden of genetic risk is a clinical problem that requires genetic counseling referral and emotional support, not just a blood test.[11]
Plain language for families. IV prostacyclin safety, pump management, alarm response, and knowing when to call the nurse. Share, print, or read aloud at the bedside.
Your loved one has pulmonary arterial hypertension — a disease that makes the blood vessels in the lungs too narrow, forcing the right side of the heart to work harder than it was designed to. Over time, the heart cannot keep up. You are watching someone you love struggle with breathlessness, fatigue, swelling, and — if they are on IV medication — a pump and tubing that are part of every moment of their day. This is frightening, exhausting, and at times overwhelming. We want you to know: the goal of care now is comfort, presence, and the best quality of life possible for every day that remains. You are not helpless. There are specific things you can do that make a real difference — and we are here to guide you through every one of them.[43]
Su ser querido tiene hipertensión arterial pulmonar — una enfermedad que estrecha los vasos sanguíneos de los pulmones y obliga al lado derecho del corazón a trabajar más de lo que fue diseñado. Estamos aquí para ayudarle.
The IV medication running through the pump is keeping your loved one's heart working. It must never be stopped suddenly. If the pump stops, alarms, or loses power, follow the emergency protocol posted in the home. This section covers what you need to know — read it carefully, practice the alarm response, and know your three emergency phone numbers before you need them.[3]
Pump alarm that does not resolve after following the posted protocol — call PAH center first, then hospice nurse. Fever above 100.4°F (38°C) — may indicate central line infection; this is a medical emergency in PAH patients on IV prostacyclin. Sudden severe shortness of breath at rest — worse than their usual baseline; may indicate acute RV decompensation. Fainting or loss of consciousness — lower them safely, call immediately. New or worsening chest pain. Confusion or difficulty waking up. Blue or gray color of lips, fingers, or face. Rapid swelling of legs or abdomen over hours. Any central line site that is red, swollen, warm, or draining. The patient expressing a wish to stop the IV medication — this requires a planned conversation with the full care team; it is not an emergency to stop, but it is an important conversation to start. Call the nurse to begin the process.
🙏 You are doing something extraordinary. Caring for someone with pulmonary arterial hypertension — managing a pump, watching for alarms, learning medical protocols you never imagined you'd need to know — is one of the hardest things a family member can do. Research consistently shows that patients who have present, engaged family members have better symptom control, less anxiety, and more peaceful deaths.[47] You are not a bystander. You are part of the care team. And the love you bring to this bedside — even when you feel helpless — is medicine that no pharmacy can fill. We are here with you, every step of the way.
Clinical field wisdom from 12+ years at the bedside. IV prostacyclin safety, PAH center coordination, the discontinuation conversation, young women with PAH, and the things you learn after doing this long enough.
50 peer-reviewed citations covering PAH epidemiology, diagnostic criteria, landmark treatment trials, palliative care approaches, and psychosocial impact. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.